Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response.

@article{Elis2010DoxorubicinIL,
  title={Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response.},
  author={Avishay Elis and Michael Lishner and Scott W. Walker and Dina Atias and Avraham Korenberg and Gideon Koren},
  journal={Therapeutic drug monitoring},
  year={2010},
  volume={32 1},
  pages={
          50-2
        }
}
Despite many years of clinical use in Hodgkin lymphoma, no previous studies have evaluated the relationship between doxorubicin pharmacokinetics and clinical response. In a pilot study, we associated the area under the curve of doxorubicin with successful remission. Patients with successful remission (n = 14) had a trend toward a higher median area under the curve than those who failed remission (n = 4; 36,390 versus 19,350 ng/mL x minute, P = 0.08, respectively). Median peak serum… CONTINUE READING